RxDoctor Payments Data

Ashish Shah, MD

Interventional Cardiology · Newburyport, MANPI 1538328166

Payments from drug & device makers

$2,305in general payments, 2019–2025

Across 16 payments — averaging $144.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Biosense Webster, Inc.$792
  • Endologix LLC$150
  • Bone Support Inc.$142
  • Novartis$40
  • AstraZeneca$34
  • plus $98 from 4 others

What the payments were for

  • Consulting fees$1,05046%
  • Travel & lodging$76133%
  • Food & beverage$48021%
  • Education$141%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,305 in reported general payments places this provider in the 35th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$48,174
Medicare patients
278
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$119,948
XareltoRivaroxaban51$75,767
EntrestoSacubitril/Valsartan44$58,995
FarxigaDapagliflozin Propanediol36$41,584
JardianceEmpagliflozin15$16,542
Repatha SureclickEvolocumab13$11,374
BrilintaTicagrelor15$10,053
Metoprolol Succinate227$5,137
Atorvastatin Calcium382$4,999
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$2,353
Ezetimibe34$2,259
Rosuvastatin Calcium44$1,354
Doxazosin Mesylate52$944
Digoxin17$768
Isosorbide Mononitrate ErIsosorbide Mononitrate35$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$24$75,76751 claims
NovartisEntresto$40$58,99544 claims
AstraZenecaFarxiga, Brilinta$34$51,63751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in Newburyport

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →